Estrogen-independent activation of estrogen receptors

Hypertension

Volumn 57, Issue 6, 2011, Pages 1056-1057

  Barton, Matthias ^a   Meyer, Matthias R ^a,b   Prossnitz, Eric R ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

AT1 receptor; estrogen receptor; GPR30; ICI 182 780; menopause; olmesartan; stroke

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; NEBIVOLOL; OLMESARTAN;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; DIABETES MELLITUS; EDITORIAL; HYPERTENSION; NEUROPROTECTION; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STROKE; VASCULAR DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; BRAIN; BRAIN ISCHEMIA; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION; IMIDAZOLES; MODELS, BIOLOGICAL; OVARIECTOMY; PEPTIDYL-DIPEPTIDASE A; PYRAZOLES; RATS; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 79956338552     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.173427     Document Type: Editorial

References (17)

1. Wise PM, Dubal DB, Rau SW, Brown CM, Suzuki S. Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's Health Initiative. Endocr Rev. 2005;26:308-312. (Pubitemid 40686644)
2. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54:11-18.
3. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod. 2002;67:1379-1385. (Pubitemid 35204912)
4. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006;47:1019-1026. (Pubitemid 44289154)
5. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR, Zimpelmann J, Gao W, Cattran DC, Scholey JW. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17:2554-2560. (Pubitemid 44300971)
6. Shenoy V, Grobe JL, Qi Y, Ferreira AJ, Fraga-Silva RA, Collamat G, Bruce E, Katovich MJ. 17β-Estradiol modulates local cardiac renin-angiotensin system to prevent cardiac remodeling in the DOCA-salt model of hypertension in rats. Peptides. 2009;30:2309-2315.
7. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005;45:545-551. (Pubitemid 40411257)
8. Chappell MC, Gallagher PE, Averill DB, Ferrario CM, Brosnihan KB. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension. 2003;42:781-786. (Pubitemid 37237325)
9. Mecawi AS, Lepletier A, Araujo IG, Fonseca FV, Reis LC. Oestrogenic influence on brain AT1 receptor signalling on the thirst and sodium appetite in osmotically stimulated and sodium-depleted female rats. Exp Physiol. 2008;93:1002-1010. (Pubitemid 352000274)
10. Shimada K, Kitazato KT, Kinouchi T, Yagi K, Tada Y, Satomi J, Kageji T, Nagahiro S. Activation of estrogen receptor-α and of angiotensinconverting enzyme 2 suppresses ischemic brain damage in oophorectomized rats. Hypertension. 2011;57:1161-1166.
11. Garban HJ, Buga GM, Ignarro LJ. Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol. 2004;43:638-644. (Pubitemid 38534063)
12. Cheng XW, Song H, Sasaki T, Hu L, Inoue A, Bando YK, Shi G-P, Kuzuya M, Okumura K, Murohara T. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension. 2011;57:981-989.
13. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor αis a major mediator of 17β-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest. 2001;107:333-340. (Pubitemid 32157965)
14. Lindsey SH, Bhat M, Aileru A, Chappell M. GPR30 attenuates AT1 receptor expression in rat mesenteric smooth muscle cells. FASEB J. 2011;25:1088.
15. Holm A, Baldetorp B, Olde B, Leeb-Lundberg LM, Nilsson BO. The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. J Vasc Res. 2011;48:327-335.
16. Mirza FS, Ong P, Collins P, Okamura K, Gerhard-Herman M, Williams GH, Seely EW. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women. Menopause. 2008;15:44-50.
17. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.